SCHEMBL4408095

SCHEMBL4408095

COc1cc(C)cc(O)c1C(C)=O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.68
SMN1; SMN2 Q16637 2/20 0.68
MAPK1 P28482 2/20 0.68
USP2 O75604 1/20 0.68
POLB P06746 4/20 0.53
RECQL P46063 3/20 0.53
GAA P10253 3/20 0.53
HTT P42858 1/20 0.48
MEN1 O00255 1/20 0.47
HPGD P15428 1/20 0.47
KMT2A Q03164 1/20 0.47
KDM4E B2RXH2 2/20 0.46
ABL1 P00519 2/20 0.46
MAPT P10636 2/20 0.46
RIN1 Q13671 2/20 0.46
NPC1 O15118 1/20 0.46
PKM P14618 1/20 0.46
BLM P54132 1/20 0.46
BCL2L1 Q07817 1/20 0.46
MCL1 Q07820 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29788586 1.00 CYP3A4 (0.68) CYP3A4SMN1; SMN2MAPK1USP2POLB
SCHEMBL12248741 0.88 CYP3A4 (0.60) CYP3A4SMN1; SMN2MAPK1USP2POLB
SCHEMBL8329910 0.83 POLB (0.63) CYP3A4SMN1; SMN2MAPK1USP2POLB
SCHEMBL16644713 0.82 CYP3A4 (0.55) CYP3A4SMN1; SMN2MAPK1USP2POLB
SCHEMBL29757572 0.82 CYP3A4 (0.76) CYP3A4SMN1; SMN2MAPK1USP2POLB
SCHEMBL1937218 0.82 CYP3A4 (0.76) CYP3A4SMN1; SMN2MAPK1USP2POLB
SCHEMBL3411846 0.81 CYP3A4 (0.46) CYP3A4SMN1; SMN2MAPK1USP2POLB
SCHEMBL1682172 0.81 CYP3A4 (0.68) CYP3A4SMN1; SMN2MAPK1USP2POLB
Xanthoxylin SCHEMBL29349586 0.81 CYP3A4 (1.00) CYP3A4SMN1; SMN2MAPK1USP2POLB
Xanthoxylin SCHEMBL44708 0.81 CYP3A4 (1.00) CYP3A4SMN1; SMN2MAPK1USP2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11643405-B2 Compound for treatment or prevention of liver diseases JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2023-05-09 US disclosed
EP-3411036-B1 3,5-DISUBSTITUTED PYRAZOLES USEFUL AS CHECKPOINT KINASE 1 (CHK1) INHIBITORS, AND THEIR PREPARATIONS AND APPLICATIONS PHARMAENGINE INC (TW) 2021-12-29 EP disclosed
US-11116767-B2 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (Chk1) inhibitors, and their preparations and applications PHARMAENGINE, INC. (TW) 2021-09-14 US disclosed
US-20210137918-A1 3,5-DISUBSTITUTED PYRAZOLES USEFUL AS CHECKPOINT KINASE 1 (CHK1) INHIBITORS, AND THEIR PREPARATIONS AND APPLICATIONS PHARMAENGINE, INC. (TW) 2021-05-13 US disclosed
US-9868715-B2 Apigenin analogs, compositions, and methods related thereto THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMS (US) 2018-01-16 US disclosed
US-20170204078-A1 APIGENIN ANALOGS, COMPOSITIONS, AND METHODS RELATED THERETO THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2017-07-20 US disclosed
US-20150056166-A1 FLAVONE DERIVATIVES AND THEIR USE TWINCORE GMBH (DE) 2015-02-26 US disclosed
US-20090270435-A1 Spiroketone Acetyl-CoA Carboxylase Inhibitors CORBETT JEFFREY WAYNE 2009-10-29 US disclosed
EP-2097420-A1 SPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS Pfizer Products Inc. (US) 2009-09-09 EP disclosed
WO-2008065508-A1 SPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS PFIZER PRODUCTS INC. (US) 2008-06-05 WO disclosed
US-6552054-B1 For prophylaxis and therapy of bone diseases and chondropathy TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-04-22 US disclosed
EP-1211251-A1 CHROMONE DERIVATIVES, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF Takeda Chemical Industries, Ltd. (JP) 2002-06-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210137918-A1 3,5-DISUBSTITUTED PYRAZOLES USEFUL AS CHECKPOINT KINASE 1 (CHK1) INHIBITORS, AND THEIR PREPARATIONS AND APPLICATIONS CHEK1, CHEK2, BUB1 CYP3A4 2547/4885SMN1; SMN2 4253/4885MAPK1 337/4885
US-20090270435-A1 Spiroketone Acetyl-CoA Carboxylase Inhibitors ACACA, PC, ACACB CYP3A4 1414/4885SMN1; SMN2 4511/4885MAPK1 1428/4885
US-20170204078-A1 APIGENIN ANALOGS, COMPOSITIONS, AND METHODS RELATED THERETO CBS, CTH, PTGIS CYP3A4 1172/4885SMN1; SMN2 4375/4885MAPK1 2720/4885
US-11116767-B2 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (Chk1) inhibitors, and their preparations and applications CHEK1, CHEK2, BUB1 CYP3A4 2547/4885SMN1; SMN2 4253/4885MAPK1 337/4885
US-11643405-B2 Compound for treatment or prevention of liver diseases SLC10A1, GYS2, CPT1A CYP3A4 187/4885SMN1; SMN2 2676/4885MAPK1 2177/4885
US-20150056166-A1 FLAVONE DERIVATIVES AND THEIR USE MAVS, ZC3HAV1, EBNA1BP2 CYP3A4 402/4885SMN1; SMN2 3284/4885MAPK1 1027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.